Nine Masts Capital
ALXO icon

Nine Masts Capital’s ALX Oncology ALXO Stock Holding History

Nine Masts Capital’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20,623
Closed -$41.3K – 174
2026
Q1 		$41.3K Buy
20,623
+5,148
+33% +$9.8K 0.01% 173
2025
Q4 		$17.5K Buy
+15,475
New +$23.4K ﹤0.01% 116

Other funds holding ALXO

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
venBio Partners
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Redmile Group
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $39B AUM 18.55% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Silverarc Capital Management
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.65% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vivo Capital
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Nine Masts Capital's ALXO Position: Q2 2026 in Review

Nine Masts Capital sold out of ALX Oncology (ALXO) in Q2 2026, closing a stake of 20,623 shares — an estimated $41.3K sold.

Nine Masts Capital first reported a position in ALXO in Q4 2025 and held it in 2 quarters. The position peaked at $41.3K in Q1 2026. 93 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

  • Nine Masts Capital reported no remaining ALX Oncology position as of Q2 2026 after selling out during the quarter.
  • Nine Masts Capital sold 20,623 ALX Oncology shares in Q2 2026, an estimated $41.3K.
  • Nine Masts Capital first reported a position in ALX Oncology in Q4 2025 and held it in 2 quarters.
  • Nine Masts Capital's ALX Oncology position peaked at $41.3K in Q1 2026.
  • 93 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on Nine Masts Capital's 13F filing for Q2 2026, filed 7 Aug 2026.